Markets are Closed
Company Logo
CELG
Celgene Corporation

Open

Previous Open

High

Previous High

Low

Previous Low

Close

Previous Close

Volume

Previous Volume

Company Profile

Description

Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Exchange

Nasdaq Global Select

List Date

January 03, 1994

CEO

Mark J. Alles

Employees

7,467

Financials

Revenue

15.28B

Earnings

5.57B
14B
11B
8B
5B
2B
2014
2015
2016
2017

Splits

February 27, 20060.50%
October 25, 20040.50%
April 17, 20000.33%

Dividends

No dividends paid to date

Related News

News post image: Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company
Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company
Jan 14, 2020 @ 18:02
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future....
finance yahoo
News post image: NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation
NASDAQ: CELG Investor Notice: Update in Lawsuit against Celgene Corporation announced by Shareholders Foundation
Jan 07, 2020 @ 12:10
SAN DIEGO, CA / ACCESSWIRE / January 7, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Celgene Corporation (CELG) shares. Investors, who purchased shares of Celgene Corporation (CELG) in 2016 or earlier and continue to hold any of your NASDAQ: CELG...
finance yahoo
News post image: An Unusual Investment With 125% Upside
An Unusual Investment With 125% Upside
Dec 30, 2019 @ 15:35
Discussion of the Bristol-Myers contingent value right Continue reading......
finance yahoo
News post image: Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise
Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise
Dec 09, 2019 @ 14:02
Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year....
finance yahoo
News post image: Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
Dec 04, 2019 @ 13:00
Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?...
finance yahoo
News post image: Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
Nov 26, 2019 @ 08:09
There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road....
finance yahoo
News post image: Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
Nov 21, 2019 @ 22:58
Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition....
finance yahoo
News post image: Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut
Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut
Nov 21, 2019 @ 22:20
The contingent value rights debuted with a bang on the New York Stock Exchange Thursday, with heavy trading volume of 101 million amid selling by index funds....
finance yahoo
News post image: Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy
Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy
Nov 21, 2019 @ 21:28
Amgen raised its full-year outlook Thursday after the biotech company wrapped its acquisition of psoriasis treatment Otezla in the wake of Bristol-Myers Squibb's takeover of Celgene....
finance yahoo
News post image: Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug
Nov 21, 2019 @ 11:41
Amgen Inc on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla. Bristol-Myers Squibb Co, which completed its buyout of Celgene on Wednesday, had agreed to divest the drug for the merger to go through...
finance yahoo